HER2+ Breast Cancer Treatment Algorithm
Panelists discuss how HER2-positive (HER2+) breast cancer treatment typically follows a targeted approach combining anti-HER2 therapy (trastuzumab [Herceptin]) with chemotherapy. Early-stage disease utilizes neoadjuvant/adjuvant therapy, whereas metastatic cases may require additional HER2-targeted agents. Treatment plans are individualized based on stage, hormone receptor status, and patient factors.
EP. 1: Early-Stage HER2+ Breast Cancer Treatment
February 17th 2025Panelists discuss how, for early-stage HER2-positive breast cancer, standard treatment typically combines surgery with targeted therapy (like trastuzumab/Herceptin), chemotherapy, and often radiation. This multi-modal approach, tailored to individual factors, has significantly improved survival rates for this aggressive subtype.
EP. 2: Locally Advanced HER2+ Breast Cancer
February 17th 2025Panelists discuss how, locally advanced HER2-positive breast cancer is characterized by overexpression of HER2 proteins with regional spread beyond the primary tumor, involving either extensive lymph node involvement, chest wall, or skin, but without distant metastases. Treatment typically combines targeted HER2 therapy, chemotherapy, and local interventions.
EP. 3: Escalating to TDM-1 Treatment Therapy
February 17th 2025Panelists discuss how, TDM-1 (Trastuzumab emtansine/Kadcyla) is an antibody-drug conjugate used in HER2-positive breast cancer treatment. This targeted therapy combines Herceptin's cancer-cell targeting ability with a potent chemotherapy drug, delivering treatment directly to cancer cells while minimizing damage to healthy tissue.
EP. 4: Approach to HER2+ Metastatic Disease Treatment
February 17th 2025Panelists discuss how; the treatment of HER2-positive metastatic breast cancer typically involves HER2-targeted therapies combined with chemotherapy. First-line treatment usually consists of trastuzumab plus pertuzumab with a taxane. Subsequent lines may include T-DM1, tucatinib-based combinations, or other HER2-directed therapies, with treatment selection guided by disease characteristics and prior therapy response.
EP. 5: Navigating Data Free HER2+ Breast Cancer Treatment
February 17th 2025Panelists discuss how, data-free navigation of HER2+ breast cancer treatment requires careful consideration of established guidelines while accounting for individual patient factors. Treatment typically follows a multimodal approach, combining targeted HER2 therapies, chemotherapy, and surgery based on clinical expertise.
